Warfarin–Antibiotic Interaction in an Elderly Patient with CrCl 28 mL/min
A 78-year-old woman (weight 54 kg, serum creatinine 1.6 mg/dL, estimated CrCl 28 mL/min) attends the anticoagulation clinic. She has been stable on warfarin 4 mg daily for 2 years with INR 2.3–2.8 (target 2.5). She presents today with a 3-day history of dysuria, urinary frequency, and low-grade fever. Urine culture is pending. Her other medicines are amlodipine 5 mg, atorvastatin 20 mg, and omeprazole 20 mg. The physician asks you to recommend empiric therapy for an uncomplicated urinary tract infection while she continues warfarin. Her INR today is 2.6 and she reports no bleeding.
1. Which empiric antibiotic would you recommend, and which agents would you avoid? Justify each choice with respect to her renal function and warfarin.
Read the worked answer
Avoid TMP-SMX. Trimethoprim–sulfamethoxazole is the classic warfarin potentiator: sulfamethoxazole inhibits CYP2C9 (warfarin's S-enantiomer metabolism), and trimethoprim adds displacement from albumin. INR rises of 2–3-fold within days are well documented. It also accumulates in CrCl <30 mL/min.
Avoid fluoroquinolones as first line. Ciprofloxacin and levofloxacin inhibit CYP1A2/CYP3A4 and have been associated with INR elevation and bleeding; they also carry QT and tendinopathy risks in elderly patients and require dose adjustment at CrCl 28 mL/min.
Avoid nitrofurantoin. Contraindicated at CrCl <30 mL/min (inadequate urinary concentrations, increased toxicity).
Reasonable choice: fosfomycin trometamol 3 g single dose. It has no CYP-mediated interaction with warfarin, no renal dose adjustment needed, and is appropriate for uncomplicated cystitis. Alternatively, pivmecillinam or a short course of amoxicillin (if susceptible) could be used. Recommend culture-directed therapy once results return.
Practical plan: confirm no allergy, counsel on signs of bleeding, recheck INR in 3–5 days after any new antibiotic, and avoid adding interacting agents.
2. The patient's INR 5 days later is 5.8 with no bleeding. What is your management, and what monitoring do you institute?
Read the worked answer
Assessment: INR 5.8 without bleeding = supratherapeutic but not yet in the urgent-reversal category (which is typically INR >10 or any bleeding).
Management (per standard anticoagulation guidance):
- Withhold 1–2 warfarin doses.
- Consider low-dose oral vitamin K (1–2.5 mg) if high bleeding risk or if INR is rising; for INR 5–9 without bleeding, vitamin K is optional and often reserved for patients with additional risk factors (recent surgery, thrombocytopenia, prior bleeding).
- Do not give fresh frozen plasma or prothrombin complex concentrate in a non-bleeding patient.
- Resume at a reduced dose (e.g., 3 mg daily or an alternating regimen) once INR is in range, guided by the calculated weekly dose reduction (~10–15%).
Monitoring:
- Recheck INR in 24–48 h after vitamin K and again in 3–7 days.
- Weekly INR until two consecutive in-range values, then extend.
- Screen for bleeding (bruising, hematuria, melena, headache).
- Reinforce avoidance of NSAIDs, aspirin unless indicated, and interacting antibiotics; document the interaction in the record.
3. The culture returns E. coli susceptible only to nitrofurantoin, ciprofloxacin, and TMP-SMX. How do you advise the prescriber?
Read the worked answer
All three options carry problems in this patient:
- Nitrofurantoin: CrCl 28 mL/min - below the usual 30 mL/min threshold; efficacy is reduced because urinary concentration falls, and toxicity (pulmonary, hepatic, neuropathic) rises. Generally avoid.
- TMP-SMX: CYP2C9 inhibition plus renal accumulation; high risk of major INR elevation on warfarin.
- Ciprofloxacin: CYP1A2/3A4 inhibition, QT risk, tendinopathy in elderly; requires dose adjustment for CrCl 28 mL/min.
Recommendation: If the infection is mild and the patient is stable, consider culture-directed ciprofloxacin with dose adjustment (e.g., 250 mg twice daily for 3 days for cystitis) plus intensified INR monitoring (check at 3 and 5–7 days) and patient education on bleeding signs. If a beta-lactam-susceptible alternative exists on repeat culture, prefer it. If the patient is systemically unwell or has pyelonephritis features, escalate to IV therapy with ID input.
Key teaching point: in a renally impaired, warfarinised patient, the 'susceptible' list is not the same as the 'safe' list - you must reconcile susceptibility, renal function, and drug-interaction risk.